$SLDB
Solid Biosciences Inc.

2022 Q4 Form 10-Q Financial Statement

#000095017022024163 Filed on November 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $0.00 $0.00 $3.537M
YoY Change -100.0% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.618M $7.127M $7.143M
YoY Change 5.64% -0.22% 37.9%
% of Gross Profit
Research & Development $21.29M $14.01M $14.43M
YoY Change 45.87% -2.91% -10.12%
% of Gross Profit
Depreciation & Amortization $539.0K $438.0K $752.0K
YoY Change -29.08% -41.76% -1.83%
% of Gross Profit
Operating Expenses $28.91M $21.13M $21.57M
YoY Change 32.57% -2.02% 1.59%
Operating Profit -$21.13M -$18.03M
YoY Change 17.2%
Interest Expense $2.616M
YoY Change 3987.5%
% of Operating Profit
Other Income/Expense, Net $19.42M $722.0K $48.00K
YoY Change -88350.0% 1404.17%
Pretax Income -$15.15M -$20.41M -$17.98M
YoY Change -18.59% 13.5% -15.37%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$15.15M -$20.41M -$17.98M
YoY Change -18.59% 13.5% -15.36%
Net Earnings / Revenue -508.43%
Basic Earnings Per Share -$2.71 -$2.40
Diluted Earnings Per Share -$1.32 -$2.71 -$160.1K
COMMON SHARES
Basic Shares Outstanding 7.535M 113.0M 7.488M
Diluted Shares Outstanding 7.533M 7.488M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $213.7M $142.2M $229.8M
YoY Change 2.86% -38.13% 826.45%
Cash & Equivalents $155.4M $48.79M $109.7M
Short-Term Investments $58.34M $93.37M $120.1M
Other Short-Term Assets $5.916M $5.352M $8.456M
YoY Change -59.82% -36.71% 252.33%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00 $594.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $219.6M $147.5M $238.8M
YoY Change -1.34% -38.23% 777.98%
LONG-TERM ASSETS
Property, Plant & Equipment $9.657M $6.266M $6.886M
YoY Change 49.44% -9.0% -22.36%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $175.0K $422.0K $2.072M
YoY Change 86.17% -79.63% 314.4%
Total Long-Term Assets $40.61M $36.97M $10.18M
YoY Change 315.79% 263.26% -23.49%
TOTAL ASSETS
Total Short-Term Assets $219.6M $147.5M $238.8M
Total Long-Term Assets $40.61M $36.97M $10.18M
Total Assets $260.3M $184.5M $249.0M
YoY Change 11.99% -25.91% 514.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.238M $5.150M $4.148M
YoY Change -27.45% 24.16% 1.17%
Accrued Expenses $16.69M $10.28M $8.003M
YoY Change 75.18% 28.39% -6.4%
Deferred Revenue $0.00
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $668.0K $353.0K $226.0K
YoY Change 187.93% 56.19% 13.0%
Total Short-Term Liabilities $22.51M $16.93M $22.54M
YoY Change -4.63% -24.92% 52.31%
LONG-TERM LIABILITIES
Long-Term Debt $1.703M $0.00 $353.0K
YoY Change 481.23% -100.0% -41.17%
Other Long-Term Liabilities $96.00K $24.27M $2.728M
YoY Change -65.09% 789.81% -5.93%
Total Long-Term Liabilities $96.00K $24.27M $3.081M
YoY Change -83.1% 687.86% -11.97%
TOTAL LIABILITIES
Total Short-Term Liabilities $22.51M $16.93M $22.54M
Total Long-Term Liabilities $96.00K $24.27M $3.081M
Total Liabilities $48.59M $41.20M $25.62M
YoY Change 101.03% 60.79% 40.02%
SHAREHOLDERS EQUITY
Retained Earnings -$562.7M -$547.6M -$458.1M
YoY Change 18.03% 19.52% 19.56%
Common Stock $774.5M $691.1M
YoY Change 13.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $211.7M $143.3M $223.4M
YoY Change
Total Liabilities & Shareholders Equity $260.3M $184.5M $249.0M
YoY Change 11.99% -25.91% 514.51%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$15.15M -$20.41M -$17.98M
YoY Change -18.59% 13.5% -15.36%
Depreciation, Depletion And Amortization $539.0K $438.0K $752.0K
YoY Change -29.08% -41.76% -1.83%
Cash From Operating Activities -$34.48M -$20.43M -$18.42M
YoY Change 65.18% 10.88% 18.33%
INVESTING ACTIVITIES
Capital Expenditures $856.0K -$839.0K -$237.0K
YoY Change -229.7% 254.01% 196.25%
Acquisitions
YoY Change
Other Investing Activities $66.96M $15.75M -$72.27M
YoY Change 117.14% -121.79%
Cash From Investing Activities $66.10M $14.91M -$72.51M
YoY Change 119.05% -120.56% 90537.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 74.74M -1.000K 3.000K
YoY Change 113137.88% -133.33%
NET CHANGE
Cash From Operating Activities -34.48M -20.43M -18.42M
Cash From Investing Activities 66.10M 14.91M -72.51M
Cash From Financing Activities 74.74M -1.000K 3.000K
Net Change In Cash 106.4M -5.521M -90.93M
YoY Change 1035.32% -93.93% 481.03%
FREE CASH FLOW
Cash From Operating Activities -$34.48M -$20.43M -$18.42M
Capital Expenditures $856.0K -$839.0K -$237.0K
Free Cash Flow -$35.34M -$19.59M -$18.19M
YoY Change 74.81% 7.71% 17.41%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Local Phone Number
LocalPhoneNumber
337-4680
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001707502
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38360
dei Entity Registrant Name
EntityRegistrantName
Solid Biosciences Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
90-0943402
dei Entity Address Address Line1
EntityAddressAddressLine1
500 Rutherford Avenue
dei Entity Address City Or Town
EntityAddressCityOrTown
Third FloorCharlestown
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02129
dei City Area Code
CityAreaCode
617
dei Security12b Title
Security12bTitle
Common Stock $0.001 par value per share
dei Trading Symbol
TradingSymbol
SLDB
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7534892
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
48790000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
119136000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
93367000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
88643000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5115000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14723000
CY2022Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
237000
CY2021Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
110000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
147509000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
222612000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6266000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6462000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
28444000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1142000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
422000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
94000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1833000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2070000
CY2022Q3 us-gaap Assets
Assets
184474000
CY2021Q4 us-gaap Assets
Assets
232380000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
5150000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4463000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10275000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9528000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1062000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1263000
CY2022Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
353000
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
232000
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
85000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
35000
CY2022Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
0
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
8080000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
16925000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
23601000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
24274000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
275000
CY2022Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
0
CY2021Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
293000
CY2022Q3 us-gaap Liabilities
Liabilities
41199000
CY2021Q4 us-gaap Liabilities
Liabilities
24169000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7533081
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7533081
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7356017
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7356017
CY2022Q3 sldb Pre Funded Warrants Outstanding
PreFundedWarrantsOutstanding
0
CY2021Q4 sldb Pre Funded Warrants Outstanding
PreFundedWarrantsOutstanding
143888
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
8000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
691050000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
685006000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-196000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-45000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-547587000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-476757000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
143275000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
208211000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
184474000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
232380000
CY2021Q3 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
3537000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
8094000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
10466000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14005000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14425000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
57130000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44144000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7127000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7143000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21330000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19924000
us-gaap Restructuring Charges
RestructuringCharges
1520000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
21132000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
21568000
us-gaap Operating Expenses
OperatingExpenses
79980000
us-gaap Operating Expenses
OperatingExpenses
64068000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1056000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-21132000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-18031000
us-gaap Operating Income Loss
OperatingIncomeLoss
-71886000
us-gaap Operating Income Loss
OperatingIncomeLoss
-53602000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
722000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
48000
us-gaap Profit Loss
ProfitLoss
-53578000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
24000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-20410000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-17983000
us-gaap Profit Loss
ProfitLoss
-70830000
us-gaap Profit Loss
ProfitLoss
-53578000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.71
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.71
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.40
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.40
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.42
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.42
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.68
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.68
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7532706
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7532706
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7487531
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7487531
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7521411
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7521411
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6980453
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6980453
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-20410000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-17983000
us-gaap Profit Loss
ProfitLoss
-70830000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-74000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-11000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-151000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-22000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-20484000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-17994000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-70981000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-53600000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
162235000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1524000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-74000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-20410000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
143275000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
208211000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5950000
sldb Pre Funded Warrants Exercise During Period Value
PreFundedWarrantsExerciseDuringPeriodValue
22000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
73000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-151000
us-gaap Profit Loss
ProfitLoss
-70830000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
143275000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
237938000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3416000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-11000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-17983000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
223363000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
132086000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9958000
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
8872000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
134878000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
41000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-22000
us-gaap Profit Loss
ProfitLoss
-53578000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
223363000
us-gaap Profit Loss
ProfitLoss
-70830000
us-gaap Profit Loss
ProfitLoss
-53578000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-509000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-535000
us-gaap Share Based Compensation
ShareBasedCompensation
5950000
us-gaap Share Based Compensation
ShareBasedCompensation
9958000
us-gaap Depreciation
Depreciation
1869000
us-gaap Depreciation
Depreciation
2204000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-9000
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
249000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3301000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1639000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-110000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
594000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
660000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
639000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3263000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-4831000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-8080000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-9593000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-63497000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-56890000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2159000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
621000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
600000
us-gaap Payments For Proceeds From Availableforsale Securities Shortterm
PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm
-157766000
us-gaap Payments For Proceeds From Availableforsale Securities Shortterm
PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm
-3930000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
163150000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
124571000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6943000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-121262000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
134878000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
22000
sldb Employee Stock Purchases And Withholding
EmployeeStockPurchasesAndWithholding
72000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
41000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
94000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
134919000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-70346000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2070000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
48790000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
119136000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
109676000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
154744000
CY2022Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
237000
CY2021Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
90000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1833000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-43233000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
121206000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
155071000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
50860000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
111838000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
29126000
sldb Increase Decrease In Right Of Use Asset Due To Lease Termination
IncreaseDecreaseInRightOfUseAssetDueToLeaseTermination
-464000
sldb Increase Decrease In Right Of Use Asset Due To Lease Termination
IncreaseDecreaseInRightOfUseAssetDueToLeaseTermination
-1233000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
217000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
345000
sldb Mission Description
MissionDescription
The Company’s mission is to cure Duchenne muscular dystrophy (“Duchenne”), a genetic muscle-wasting disease predominantly affecting boys.
sldb Medicine Description
MedicineDescription
In March 2022, the Company reported two-year interim safety and efficacy data from the first three patients treated with SGT-001 in the 2E14 vg/kg dose cohort of IGNITE DMD, which results suggested durable benefit compared with natural history trajectories 24 months post-administration of SGT-001 across functional, pulmonary and patient reported outcome measures. In addition, no new drug-related safety findings have been identified in patients treated with SGT-001 in IGNITE DMD in post-dosing periods of approximately twelve months to four years. In April 2022, the Company announced that it had concluded enrollment in IGNITE DMD and in September 2022, the Company announced that it would be pausing activities for SGT-001. The Company intends to complete currently ongoing SGT-001 preclinical and manufacturing activities in order to be in a position to reactivate the program in the future, if desired.
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-547587000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-20410000
us-gaap Profit Loss
ProfitLoss
-70830000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-63497000
CY2022Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
142157000
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, estimates related to revenue recognition, the recognition of research and development expenses and equity-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from the Company’s estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including clinical trials and employee-related amounts, will depend on future developments that are highly uncertain, including new information that may emerge concerning COVID-19 and the actions taken to contain it or treat its impact. The Company has made estimates of the impact of COVID-19 within its financial statements and there may be changes to those estimates in future periods. Actual results could differ from the Company’s estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2022Q3 us-gaap Deposit Assets
DepositAssets
2070000
CY2021Q4 us-gaap Deposit Assets
DepositAssets
2070000
CY2022Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
237000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1833000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2070000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2072000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
327000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
50860000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
121206000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
111838000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
155071000
CY2022Q3 us-gaap Related Party Costs
RelatedPartyCosts
299000
us-gaap Related Party Costs
RelatedPartyCosts
803000
CY2021Q3 us-gaap Related Party Costs
RelatedPartyCosts
194000
us-gaap Related Party Costs
RelatedPartyCosts
381000
CY2020Q4 sldb Common Stock Shares Issued Warrant To Purchase
CommonStockSharesIssuedWarrantToPurchase
2000
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
49.35
sldb Agreement Termination Period
AgreementTerminationPeriod
P60D
sldb Agreement Written Notice Period
AgreementWrittenNoticePeriod
P30D
CY2022Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
33185000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
93367000
CY2022Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
126552000
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
75224000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
88643000
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
163867000
CY2022Q3 sldb Fair Value Asset Level1 To Level2 Transfers Amount
FairValueAssetLevel1ToLevel2TransfersAmount
0
CY2022Q3 sldb Fair Value Asset Level2 To Level1 Transfers Amount
FairValueAssetLevel2ToLevel1TransfersAmount
0
CY2021Q4 sldb Fair Value Asset Level1 To Level2 Transfers Amount
FairValueAssetLevel1ToLevel2TransfersAmount
0
CY2021Q4 sldb Fair Value Asset Level2 To Level1 Transfers Amount
FairValueAssetLevel2ToLevel1TransfersAmount
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
93562000
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
195000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
93367000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
88688000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
45000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
88643000
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis
93562000
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
93367000
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
93562000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
93367000
sldb Available For Sale Securities Weighted Average Maturity Period
AvailableForSaleSecuritiesWeightedAverageMaturityPeriod
P0Y6M
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis
88688000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
88643000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
88688000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
88643000
CY2021 sldb Available For Sale Securities Weighted Average Maturity Period
AvailableForSaleSecuritiesWeightedAverageMaturityPeriod
P0Y8M12D
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
15683000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
18123000
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9417000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11661000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6266000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6462000
CY2022Q3 us-gaap Depreciation
Depreciation
438000
us-gaap Depreciation
Depreciation
1869000
CY2021Q3 us-gaap Depreciation
Depreciation
752000
us-gaap Depreciation
Depreciation
2204000
CY2022Q3 sldb Prepaid Research And Development Expenses Current
PrepaidResearchAndDevelopmentExpensesCurrent
2514000
CY2021Q4 sldb Prepaid Research And Development Expenses Current
PrepaidResearchAndDevelopmentExpensesCurrent
6015000
CY2022Q3 sldb Prepaid Expense And Other Assets Miscellaneous Current
PrepaidExpenseAndOtherAssetsMiscellaneousCurrent
2601000
CY2021Q4 sldb Prepaid Expense And Other Assets Miscellaneous Current
PrepaidExpenseAndOtherAssetsMiscellaneousCurrent
8708000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5115000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14723000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10275000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9528000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1440
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
303300
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
30553
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
230649
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1524000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3416000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5950000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9958000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20410000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17983000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-70830000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-53578000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7532706
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7532706
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7487531
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7487531
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7521411
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7521411
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6980453
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6980453
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.71
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.71
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.40
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.40
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.42
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.42
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.68
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.68
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
701949
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
416308
CY2022Q2 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.35
CY2022Q3 us-gaap Restructuring Charges
RestructuringCharges
0
CY2022Q3 us-gaap Severance Costs1
SeveranceCosts1
1520000
us-gaap Severance Costs1
SeveranceCosts1
1520000
CY2022Q3 us-gaap Payments For Restructuring
PaymentsForRestructuring
751000
us-gaap Payments For Restructuring
PaymentsForRestructuring
1479000
CY2022Q3 sldb Remaining Accrued Restructuring Charges To Be Paid In Next Three Months
RemainingAccruedRestructuringChargesToBePaidInNextThreeMonths
41000

Files In Submission

Name View Source Status
0000950170-22-024163-index-headers.html Edgar Link pending
0000950170-22-024163-index.html Edgar Link pending
0000950170-22-024163.txt Edgar Link pending
0000950170-22-024163-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sldb-20220930.htm Edgar Link pending
sldb-20220930.xsd Edgar Link pending
sldb-ex31_1.htm Edgar Link pending
sldb-ex31_2.htm Edgar Link pending
sldb-ex32_1.htm Edgar Link pending
sldb-ex32_2.htm Edgar Link pending
sldb-20220930_def.xml Edgar Link unprocessable
sldb-20220930_lab.xml Edgar Link unprocessable
sldb-20220930_pre.xml Edgar Link unprocessable
sldb-20220930_htm.xml Edgar Link completed
sldb-20220930_cal.xml Edgar Link unprocessable